TY - JOUR
T1 - Novel antibody–drug conjugates for triple negative breast cancer
AU - Nagayama, Aiko
AU - Vidula, Neelima
AU - Ellisen, Leif
AU - Bardia, Aditya
N1 - Publisher Copyright:
© The Author(s), 2020.
PY - 2020
Y1 - 2020
N2 - Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
AB - Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
KW - antibody–drug conjugates
KW - breast cancer
KW - triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85084543532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084543532&partnerID=8YFLogxK
U2 - 10.1177/1758835920915980
DO - 10.1177/1758835920915980
M3 - Review article
AN - SCOPUS:85084543532
SN - 1758-8340
VL - 12
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -
